Factors that influence basal insulin requirement in type 2 diabetes

Acta Diabetologica

Volumn 49, Issue 5, 2012, Pages 387-393

  Papa, Giuseppe ^a   Baratta, Roberto ^b   Calì, Vincenzo ^a   Degano, Claudia ^a   Iurato, Maria Pierangela ^a   Licciardello, Carmelo ^a   Maiorana, Raffaella ^a   Finocchiaro, Concetta ^a  

^a Centro Catanese di Medicina e Chirurgia Clinic   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Basal insulin requirement; Insulin therapy; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDICATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ULTRASOUND; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; BODY WEIGHT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED;

EID: 84868000728     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0372-7     Document Type: Article

References (16)

1. Hirsch IB, Bergenstal RM, Parkin CG et al (2005) A real-world approach to insulin therapy in primary care practice. Clin Diabetes 23:78-86
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193-203
3. Riddle MC, Rosenstock J, Gerich J, On behalf of the Insulin Glargine 4002 Study Investigators (2003) Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086
4. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:408-416
5. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P, Tulokas T, Viikari J, Karjalainen J, Taskinen MR (1992) Comparison of insulin regiments in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433
6. Riddle MC, Scneider J (1998) Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone: Glimepiride Combination Group. Diabetes Care 21:1052-1057
7. Standard italiani per la cura del diabete mellito 2009-2010. Associazione Medici-Diabetologi. Società Italiana di Diabetologia. Infomedica, Torino, 2010 (http://www.siditalia.it/documenti/2010-linee-guida.pdf)
8. Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645
9. Pitocco D, Valle D, Rossi A, Gentilella R (2008) Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents. J Endocrinol Invest 31(4):371-379
10. Mooradian AD, Bernbaum M, Albert SG (2006) Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 145:125-134
11. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758
12. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005) Reversal of non-alcoholic hepatic steatosis, hepatic insulin resistance and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 3:603-608
13. Kim MK, Jang EH, Son JW, Kwon HS, Baek KH, Lee KW, Song KH (2011) Visceral obesity is a better predictor than generalized obesity for basal insulin requirement at the initiation of insulin therapy in patients with type 2 diabetes. Diabetes Res Clin Pract. doi: 10.1016/j.diabres.2011.04.009
14. Kooy A, deJager J, Lehert P, Bets D, Wulffelè MG, Donker JM, Stehouwer DA (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169(6):616-625
15. Holman RR, Turner RC (1985) A practical guide to basal and prandial insulin therapy. Diabet Med 2(1):45-53
16. Strange P (2007) Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 1(4):540-548